The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial.
 
Mazyar Shadman
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics
Research Funding - Acerta Pharma; Emergent BioSolutions; Gilead Sciences; GlaxoSmithKline; Merck; Pharmacyclics
 
Mohamed L Sorror
Honoraria - Jazz Pharmaceuticals
Consulting or Advisory Role - Jazz Pharmaceuticals
 
Brenda M. Sandmaier
Stock and Other Ownership Interests - Blaze Bioscience; Blaze Bioscience (I); EpiThany; EpiThany (I)
Consulting or Advisory Role - AREVA Med; frazier healthcare partners (I); Gilead Sciences; Jazz Pharmaceuticals; Seagen
Research Funding - Ambit BioSciences; Astellas Pharma; Bellicum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Calistoga Pharmaceuticals (I); Gilead Sciences (I)
 
Barry Storer
No Relationships to Disclose
 
Thomas R. Chauncey
No Relationships to Disclose
 
Niels Smedegaard Andersen
No Relationships to Disclose
 
Dietger Niederwieser
No Relationships to Disclose
 
Judith Shizuru
No Relationships to Disclose
 
Benedetto Bruno
No Relationships to Disclose
 
Michael Pulsipher
No Relationships to Disclose
 
Richard T. Maziarz
No Relationships to Disclose
 
Edward D. Agura
No Relationships to Disclose
 
Parameswaran Hari
Stock and Other Ownership Interests - Pharmacyclics
Honoraria - Amgen; Celgene; Millennium; Novartis; Sanofi; Spectrum Pharmaceuticals
Consulting or Advisory Role - Celgene; Millennium; Onyx; Sanofi
Research Funding - Celgene (Inst); Millennium (Inst); Onyx (Inst); Spectrum Pharmaceuticals (Inst)
 
Amelia A. Langston
No Relationships to Disclose
 
Michael B. Maris
No Relationships to Disclose
 
Peter A McSweeney
No Relationships to Disclose
 
Rainer Storb
No Relationships to Disclose
 
David G. Maloney
No Relationships to Disclose